Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer
暂无分享,去创建一个
L. Cattel | M. Airoldi | C. Bumma | F. Pedani | V. Tagini | S. Marchionatti | V. Recalenda
[1] L. Cattel,et al. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. , 2001, Farmaco.
[2] J. Bonneterre,et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Cattel,et al. Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions. , 1999, Farmaco.
[4] 青江 啓介. Effect of Docetaxel with Cisplatin or Vinorelbine on Lung Cancer Cell Lines , 1999 .
[5] H. Burris,et al. Single-agent docetaxel (Taxotere) in randomized phase III trials. , 1999, Seminars in oncology.
[6] J. Crown. Phase III randomized trials of docetaxel in patients with metastatic breast cancer. , 1999, Seminars in oncology.
[7] S. Agelaki,et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] P. Barrett-Lee,et al. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] M. Zucchetti,et al. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. , 1998, Seminars in oncology.
[10] M. R. Mir,et al. Dose-dense weekly docetaxel and CBDCA in adriamycin-resistant metastatic breast cancer (MBC) , 1998 .
[11] D. Levêque,et al. Clinical Pharmacokinetics of Vinorelbine , 1996, Clinical pharmacokinetics.
[12] L. Hutchins,et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Villani,et al. Cardiac arrhythmia and ischaemic events after combination chemotherapy for testicular cancer. , 1994, European heart journal.
[14] S. Barni,et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] W. Sawyer,et al. Reversal of multidrug resistance by surfactants. , 1992, British journal of cancer.
[16] E. Quoix,et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. , 1991, Cancer research.
[17] W. Mellado,et al. Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.
[18] C. Begg,et al. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies? , 2005, Breast Cancer Research and Treatment.
[19] A. V. van Oosterom. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. , 1995, Seminars in oncology.